Sustained clinical and histopathological remission in a patient with eosinophilic esophagitis and type 2 comorbidities after 18 months of discontinuation of dupilumab

Víctor González-UribeCarlos Acosta Rodríguez-BuenoZaira Mojica-GonzálezAndrea Malagón‐LiceagaMartín Roberto Basile-Álvarez2026-03-222026-03-22202310.22541/au.168804227.77031880/v1https://doi.org/10.22541/au.168804227.77031880/v1https://andeanlibrary.org/handle/123456789/84191enEosinophilic esophagitisDupilumabDiscontinuationMedicineGastroenterologyInternal medicineDermatologyEsophagitisEosinophiliaSustained clinical and histopathological remission in a patient with eosinophilic esophagitis and type 2 comorbidities after 18 months of discontinuation of dupilumabpreprint